Premium
Effects of lipoxin A 4 on chemotaxis and degranulation of human eosinophils stimulated by platelet‐activating factor and N ‐formyl‐L‐methionyl‐L‐leucyl‐L‐phenylalanine
Author(s) -
Soyombo O.,
Spur B. W.,
Lee T. H.
Publication year - 1994
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1994.tb02654.x
Subject(s) - lipoxin , eosinophil , chemotaxis , chemistry , platelet activating factor , n formylmethionine leucyl phenylalanine , degranulation , arachidonic acid , granulocyte , biochemistry , neutrophile , platelet , microbiology and biotechnology , immunology , biology , in vitro , enzyme , receptor , asthma
Lipoxins are trihydroxytetraene metabolites derived through a double lipoxygenation of arachidonic acid. Lipoxin A 4 (LXA 4 ) was prepared by total chemical synthesis, and its capacity to modulate eosinophil migration has been evaluated. LXA 4 is a weak and partial chemotactic agent; at 10 −6 M, it achieved about 20% of the response of 10 −6 M platelet‐activating factor (PAF). Preincubation of eosinophils with increasing doses of LXA 4 (10 −10 −10 −5 M) resulted in a concentration‐dependent inhibition of cell migration induced by 10 ‐6 M formyl‐methionyl‐leucyl‐phenylalanine (FMLP) and 10 ‐6 M PAF. The concentration of LXA 4 which produced 50% inhibition (IC 50 ) of eosinophil migration was approximately 10 ‐6 M. LXA 4 (10 ‐10 ‐10 ‐6 M) did not elicit ECP release or modulate ECP release induced by 10 ‐6 M FMLP. LXA 4 may have antiallergic properties in preventing eosinophilic migration.